DOCSLIB.ORG

Management of Psoriasis and Psoriatic Arthritis- Section 3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Management of Psoriasis and Psoriatic Arthritis- Section 3 FROM THE ACADEMY Guidelines of care for the management of psoriasis and psoriatic arthritis Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies Alan Menter, MD, Chair,a Neil J. Korman, MD, PhD,b Craig A. Elmets, MD,c StevenR.Feldman,MD,PhD,d Joel M. Gelfand, MD, MSCE,e Kenneth B. Gordon, MD,f Alice Gottlieb, MD, PhD,g John Y. M. Koo, MD,h Mark Lebwohl, MD,i HenryW.Lim,MD,j Abby S. Van Voorhees, MD,k Karl R. Beutner, MD, PhD,h,l and Reva Bhushan, PhDm Dallas, Texas; Cleveland, Ohio; Birmingham, Alabama; Winston-Salem, North Carolina; Philadelphia, Pennsylvania; Chicago and Schaumburg, Illinois; Boston, Massachusetts; San Francisco and Palo Alto, California; New York, New York; and Detroit, Michigan Psoriasis is a common, chronic, inflammatory, multi-system disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this third of 6 sections of the guidelines of care for psoriasis, we discuss the use of topical medications for the treatment of psoriasis. The majority of patients with psoriasis have limited disease (\5% body surface area involvement) and can be treated with topical agents, which generally provide a high efficacy-to-safety ratio. Topical agents may also be used adjunctively for patients with more extensive psoriasis undergoing therapy with either ultraviolet light, systemic or biologic medications. However, the use of topical agents as monotherapy in the setting of extensive disease or in the setting of limited, but recalcitrant, disease is not routinely recommended. Treatment should be tailored to meet individual patients’ needs. We will discuss the efficacy and safety of as well as offer recommendations for the use of topical corticosteroids, vitamin D analogues, tazarotene, tacrolimus, pimecrolimus, emollients, salicylic acid, anthralin, coal tar, as well as combination therapy. ( J Am Acad Dermatol 2009;60:643-59.) DISCLAIMER Adherence to these guidelines will not ensure Abbreviations used: successful treatment in every situation. Furthermore, AAD: American Academy of Dermatology HPA: hypothalamic-pituitary-adrenal (axis) these guidelines should not be deemed inclusive of PASI: Psoriasis Area and Severity Index all proper methods of care nor exclusive of other PGA: physician’s global assessment methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding the propriety of any specific therapy must be made SCOPE by the physician and the patient in light of all the This third section covers the management and circumstances presented by the individual patient. treatment of psoriasis with topical therapies. From the Baylor University Medical Center, Dallasa; Department of Department of Dermatology, Henry Ford Hospital, Detroitj; Dermatology, Murdough Family Center for Psoriasis, Depart- Department of Dermatology, University of Pennsylvania, Phil- ment of Dermatology, University Hospitals Case Medical Cen- adelphiak; Anacor Pharmaceuticals, Inc, Palo Altol; and Amer- ter, Clevelandb; Department of Dermatology, University of ican Academy of Dermatology.m Alabama at Birminghamc; Department of Dermatology, Wake Funding sources: None. Forest University School of Medicine, Winston-Salemd; Depart- The authors’ conflict of interest/disclosure statements appear at ment of Dermatology and Center for Clinical Epidemiology and the end of the article. Biostatistics, University of Pennsylvania, Philadelphiae; Division Reprint requests: Reva Bhushan, PhD, 930 E Woodfield Rd, of Dermatology, Evanston Northwestern Healthcare and De- Schaumburg, IL 60173. E-mail: [email protected]. partment of Dermatology, Northwestern University, Feinberg Published online February 17, 2009. School of Medicine, Chicagof; Tufts Medical Center, Tufts 0190-9622/$36.00 University School of Medicine, Bostong; Department of Derma- ª 2009 by the American Academy of Dermatology, Inc. tology, University of CaliforniaeSan Franciscoh; Department of doi:10.1016/j.jaad.2008.12.032 Dermatology, Mount Sinai School of Medicine, New Yorki; 643 644 Menter et al JAM ACAD DERMATOL APRIL 2009 METHOD agents which generally provide both high efficacy A work group of recognized psoriasis experts was and safety. Topical agents are also used adjunc- convened to determine the audience for and scope tively for resistant lesions in patients with more of the guideline and to identify clinical questions to extensive psoriasis who are being concurrently structure the primary issues in diagnosis and treated with either ultraviolet light or systemic management discussed in American Academy of medications. However, the use of topical agents Dermatology (AAD) psoriasis guidelines Sections as monotherapy in the setting of extensive disease 1 and 2.1,2 Work group members completed a or in the setting of limited, but recalcitrant disease is disclosure of commercial support. not routinely recommended. Treatment should be An evidence-based model was used and evidence tailored to meet individual patients’ needs. These was obtained using a search of the MEDLINE data- needs vary depending on body location, character- base spanning the years 1960 through 2008. istics of the psoriasis being treated including lesion The available evidence was evaluated using a uni- thickness, degree of erythema and amount of fied system called the Strength of Recommendation scaling, as well as patient preferences. It is impor- Taxonomy developed by editors of the US family tant to match patient expectations with practical medicine and primary care journals (ie, American considerations. Patients who wish for lifetime clear- Family Physician, Family Medicine, Journal of Family ance with no evident lesions will inevitably be Practice,andBMJ USA). This strategy was supported by disappointed with topical therapy because of the a decision of the Clinical Guidelines Task Force in 2005 need for a continuous intense topical regimen that with some minor modifications for a consistent ap- will be very difficult to carry out and maintain. proach to rating the strength of the evidence of Some patients may desire to be free from pruritus scientific studies.3 Evidence was graded using a 3- and to have a diminution in their most visible point scale based on the quality of methodology as lesions. Others may prefer only intermittent treat- follows: ment with little interest in spending considerable I. Good-quality patient-oriented evidence time to care for their psoriasis. It is important to II. Limited-quality patient-oriented evidence ascertain each patient’s goals and then to develop a III. Other evidence including consensus guidelines, strategy to help fulfill his or her expectations while opinion, or case studies also being practical and realistic. The choice of vehicle can significantly alter the Clinical recommendations were developed on the use and penetration of the medication and therefore best available evidence tabled in the guideline. alter the efficacy. Vehicle types are numerous and These are ranked as follows: may include ointments, creams, solutions, gels, A. Recommendation based on consistent and good- foams, tape, sprays, shampoos, oils, and lotions. quality patient-oriented evidence Different vehicles are indicated for different body B. Recommendation based on inconsistent or lim- sites. The optimal choice is generally the vehicle the ited-quality patient-oriented evidence individual patient will most likely use. For example, C. Recommendation based on consensus, opinion, hair-bearing areas including the scalp can be treated or case studies with solutions, foams, shampoos, sprays, oils, gels, In those situations where documented evidence- or other vehicles, with individual patients having based data are not available, we have utilized expert different preferences among these options. Some opinion to generate our clinical recommendations. patients may prefer a less greasy preparation, per- Prior guidelines on psoriasis were also evaluated.4,5 haps a cream for daytime use and may be willing to This guideline has been developed in accordance use an ointment, which is more effective but less with the AAD/AAD Association ‘‘Administrative cosmetically appealing, at night. Cultural prefer- Regulations for Evidence-based Clinical Practice ences may also make one vehicle preferred over Guidelines,’’ which include the opportunity for re- others for a given site. Occlusion of topical medica- view and comment by the entire AAD membership tions can also alter the penetration, thereby varying and final review and approval by the AAD Board of the effectiveness. The observation that flurandreno- Directors. lide 0.1%, which is a class 5 topical steroid when used in the cream or lotion formulation, functions as a class 1 topical steroid when used as a tape and has a GENERAL PRINCIPLES higher efficacy than the class 1 steroid diflorasone Approximately 80% of patients affected with diacetate ointment in the treatment of psoriasis6 psoriasis have mild to moderate disease. The ma- serves as a strong reminder of the impact of jority of these patients can be treated with topical occlusion. JAM ACAD DERMATOL Menter et al 645 VOLUME 60, NUMBER 4 Table I. Use of topical agents: The fingertip unit and how to assess quantity of topical agents needed to cover a given body surface area79 No. of Approximate fingertip body surface Area to be treated units area (%) Scalp 3 6 Face and neck 2.5 5 One hand (front and back) 12 including fingers One entire arm including 48 Fig 1. Use of topical agents—the fingertip unit and
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • An Empirical Study on Laboratory Coke Oven-Based Coal Blending for Coking with Tar Residue, Chemical Engineering Transactions, 71, 385-390 DOI:10.3303/CET1871065 386
    385 A publication of CHEMICAL ENGINEERING TRANSACTIONS VOL. 71, 2018 The Italian Association of Chemical Engineering Online at www.aidic.it/cet Guest Editors: Xiantang Zhang, Songrong Qian, Jianmin Xu Copyright © 2018, AIDIC Servizi S.r.l. ISBN 978-88-95608-68-6; ISSN 2283-9216 DOI: 10.3303/CET1871065 An Empirical Study on Laboratory Coke Oven-based Coal Blending for Coking with Tar Residue Wenqiu Liu Hebei Energy College of Vocation and Technology, Tangshan 063004, China [email protected] Tar residue is the solid waste produced in coking plants or gas generators. Utilizing tar residue as additive in coal blending for coking is an effective approach for coal coking in our country, not only improving the yield and nature of coking products, but also realizing the recycling of tar residue. In this paper, tar residue is used as additive in coal blending for coking experiments, and combined with experiments on the crucible coke, small coke oven and industrial coke oven, the influences of the addition amount of tar residue on coke yield, coke reactivity and coke strength after reaction are further analyzed. As the experiment results reveal, compared to the experiment results of crucible coke and small coke ovens, the coke yield, coke reactivity and coke strength after reaction of industrial coke ovens are all bigger, leading to potential industrialization of coal blending for coking. Moreover, the influence of the amount of tar residue on the coal tar yield rate and gas yield is the same as that of coke reactivity and coke strength after reaction. 1. Introduction With the rapid development of economy, the fast growth of iron and steel industry has led China's coke industry to accomplish extraordinary achievements (Si et al., 2017).
    [Show full text]
  • Coal Characteristics
    CCTR Indiana Center for Coal Technology Research COAL CHARACTERISTICS CCTR Basic Facts File # 8 Brian H. Bowen, Marty W. Irwin The Energy Center at Discovery Park Purdue University CCTR, Potter Center, 500 Central Drive West Lafayette, IN 47907-2022 http://www.purdue.edu/dp/energy/CCTR/ Email: [email protected] October 2008 1 Indiana Center for Coal Technology Research CCTR COAL FORMATION As geological processes apply pressure to peat over time, it is transformed successively into different types of coal Source: Kentucky Geological Survey http://images.google.com/imgres?imgurl=http://www.uky.edu/KGS/coal/images/peatcoal.gif&imgrefurl=http://www.uky.edu/KGS/coal/coalform.htm&h=354&w=579&sz= 20&hl=en&start=5&um=1&tbnid=NavOy9_5HD07pM:&tbnh=82&tbnw=134&prev=/images%3Fq%3Dcoal%2Bphotos%26svnum%3D10%26um%3D1%26hl%3Den%26sa%3DX 2 Indiana Center for Coal Technology Research CCTR COAL ANALYSIS Elemental analysis of coal gives empirical formulas such as: C137H97O9NS for Bituminous Coal C240H90O4NS for high-grade Anthracite Coal is divided into 4 ranks: (1) Anthracite (2) Bituminous (3) Sub-bituminous (4) Lignite Source: http://cc.msnscache.com/cache.aspx?q=4929705428518&lang=en-US&mkt=en-US&FORM=CVRE8 3 Indiana Center for Coal Technology Research CCTR BITUMINOUS COAL Bituminous Coal: Great pressure results in the creation of bituminous, or “soft” coal. This is the type most commonly used for electric power generation in the U.S. It has a higher heating value than either lignite or sub-bituminous, but less than that of anthracite. Bituminous coal
    [Show full text]
  • Coal Tar Pitch – Its Past, Present and Future in Commercial Roofing by Joe Mellott
    - 1 - Coal Tar Pitch – Its Past, Present and Future in Commercial Roofing By Joe Mellott Coal tar remains a desired and strong source of technology within the roofing industry, as innovative coal tar products significantly reduce associated health hazards and environmental impact. To help you better understand the role that coal tar continues to play in the commercial roofing market, this article will explore: • The history of coal tar • Its associated hazards • Hot and cold coal tar adhesive technologies • Modified coal tar pitch membrane technologies • Coal tar’s sustainability attributes A Brief History of Coal Tar In order to understand what coal tar pitch is, it’s important to understand its origins and refinement methods. Coal tar can be refined from a number of sources including coal, wood, peat, petroleum, and other organic materials. The tar is removed by burning or heating the base substance and selectively distilling fractions of the burned chemical. Distillation involves heating the substance to a point where different fractions of the substance become volatile. The fractions are then collected by condensing the fraction at a specific temperature. A base substance can be split into any number of fractions through distillation. A good example of industrial distillation is the oil refining process. Through distillation, crude oil can be separated into fractions that include gasoline, jet fuel, motor oil bases, and other specialty chemicals. Fractionation or distillation is a tried-and-true method for breaking a substance into different parts of its composition. One of the first uses of coal tar was in the maritime industry. Trees stumps were burned and the tar fractions were collected through distillation of the tar.
    [Show full text]
  • Spherical Graphite Produced by Waste Semi-Coke with Enhanced Properties As
    Electronic Supplementary Material (ESI) for Sustainable Energy & Fuels. This journal is © The Royal Society of Chemistry 2019 Spherical graphite produced by waste semi-coke with enhanced properties as anode material for Li-ion batteries Ming Shi, Zige Tai, Na Li, Kunyang Zou, Yuanzhen Chen, Junjie Sun, Yongning Liu* State Key Laboratory for Mechanical Behavior of Materials, School of Material Science and Engineering, Xi’an Jiaotong University, Xi’an 710049, PR China *Corresponding author E-mail address: [email protected] Fax: +86 29 8266 3453; Tel: +86 29 8266 4602 Fig. 1 N2 absorption/desorption profiles of (a) pristine semi-coke (SC); (b) synthetic graphite without Si (PG); and (c) synthetic graphite with 10% Si at 2300 °C (SG). Table 1 The percentage of impurity of pristine SC and SG (10% Si at 2300 °C). Content percentage / wt % samples B Si Al Ca Fe K Na Mg SC <0.1 4.25 5.5 3.3 0.8 0.3 0.09 <0.1 SG <0.1 1.01 1.9 0.1 <0.1 0.02 0.03 <0.1 Table 2 The SG capacity values with that of similar materials published in the literature. Materials Specific Capacity Rate capability Cyclic retention Ref. [mA h g-1] [mA h g-1] Spherical graphite produced 347.06 at 0.05C 329.8 at 0.1C; 317.4 at 97.7% at 0.5C after This by waste semi-coke 0.5 C and 262.3 at 1C 700 cycles work Iron‐catalyzed graphitic 306 at 0.1C 150 at rate of 2C Over 90 % after 200 1 materials from biomass cycles Carbonaceous composites 312 at 0.2C 149 at 1 C; 78 at 5C - 2 prepared by the mixture of graphite, cokes, and petroleum pitch.
    [Show full text]
  • Lecture 32: Coke Production
    NPTEL – Chemical – Chemical Technology II Lecture 32: Coke production 32.1 Introduction Coal is used as fuel for electric power generation, industrial heating and steam generation, domestic heating, rail roads and for coal processing. Coal composition is denoted by rank. Rank increases with the carbon content and decreases with increasing oxygen content. Many of the products made by hydrogenation, oxidation, hydrolysis or fluorination are important for industrial use. Stable, low cost, petroleum and natural gas supplies has arose interest in some of the coal products as upgraded fuels to reduce air pollution as well as to take advantage of greater ease of handling of the liquid or gaseous material and to utilize existing facilities such as pipelines and furnaces. 32.2 Coking of coal Raw material is Bituminous coal. It appears to have specific internal surfaces in the range of 30 to 100m2/g. Generally one ton of bituminous coal produces 1400 lb of coke. 10 gallons of tar. Chemical reaction:- 4(C3H4)n nC6H6 + 5nC + 3nH2 + nCH4 Coal Benzene Coke Lighter hydrocarbon Joint initiative of IITs and IISc – Funded by MHRD Page 1 of 9 NPTEL – Chemical – Chemical Technology II Process flow sheet: Illustrated in Figure. Figure 32.1 Flow sheet of coking of coal 32.3 Functional role of each unit (Figure 32.1): (a) Coal crusher and screening: At first Bituminous coal is crushed and screened to a certain size. Preheating of coal (at 150-250˚C) is done to reduce coking time without loss of coal quality. Briquetting increases strength of coke produced and to make non - coking or poorly coking coals to be used as metallurgical coke.
    [Show full text]
  • Projectprofile
    EPSILON CARBON PRIVATE LIMITED ECPL CoalTar Distillation -300,000tpa Karnataka ProjectProfile General TheEpsilon CarbonprivateLimited is aspiring to emergeasadynamiccompanyin India in the field of coal tar processing for manufacture ofvarious value added products. The proposed green-field Coal tar distillation plant coupledwith solidpitchmeltingunitisproposedtosetupwith Coal tar processing capacity of 300,000tpaat Toranagallu in Bellary district of Karnataka. Process Description: The coal tar are separated by distillation process. Coal tar containing several chemical compounds with major being Coal tar pitch,Naphthalene,Wash Oil, Light Oil, Phenol Oil & Anthracene oil. Following are major manufacturing of process & Products: 1. Coal Tar pitch (Binder Grade Pitch) 2. Zero QI /Impregnated Pitch 3. Naphthalene &Naphthalene sulfonate formaldehyde (NSF) 4. Oils- Carbon Black Oil (CBO) ,Light oil, Phenol oil, Wash oil , Anthracene oil By Products: 5. Sodium Phenolate 6. Ammonical water 1. Binder Grade Pitch: Soft Pitch from the bottom of pitch column is sent to pitch column for further processing to modified pitch to increase QI content and blended with required high QI pitch to produce binder grade pitch for aluminum industry. 2. Impregnated Pitch : Blending of coal tar and wash oil in specific ratio, dehydration up to 180℃ to separate moisture content in coal tar. The dehydrated mixture is transferred to settling tank for reduction of QI. (Settling tank provide draw-off valve for QI sampling). QI value less material transfer to further distillation (Removal of Oils) to produce Impregnated Pitch. Project Profile for 300,000 tpa Coal Tar Distillation plant EPSILON CARBON PRIVATE LIMITED ECPL CoalTar Distillation -300,000tpa Karnataka ProjectProfile 3. Carbon Black Oil(CBO): Blending of Soft Pitch from the bottom of pitch column and Anthracene oil in specific ratio with required specific gravity to produce carbon black oil for tyre industry.
    [Show full text]
  • Interpreting Tar Patterns at Former Manufactured Gas Plant Sites
    1 Interpreting Tar Patterns at Former Manufactured Gas Plant Sites Brian L. Murphy, Ph.D. • INEF, Penn State • June 10, 2013 2 Why focus on tar? . Dense, nonaqueous-phase liquid (DNAPL) that can sink into the saturated zone and contaminate groundwater – Expensive to remediate . Insurance coverage litigation – How tar got there? (Expected and intended?) – When tar got there? (During coverage period?) – Is it still moving? (During coverage period?) 3 Outline . What is manufactured gas plant (MGP) tar? . How “tarry” is it? . How fast does it move? – Distance and time scales . How to interpret boring logs in terms of tar motion . How can you identify source locations at a site where tar has migrated? 4 Nomenclature . “Tar” generally = Density > Water . “Oil” generally = Density < Water . “Coal tar” = Tar from different processes – Coal gasification – Water gas – Carbureted water gas – Oil gas Which may not involve the use of coal at all! 5 Different Processes for Manufacturing Gas . Coal gas: Heat coal in the absence of oxygen . Water gas (blue gas): Steam sprayed on incandescent coke H2O+C→CO+H2 . Carbureted water gas: Petroleum is cracked and added to water gas—most popular Lowe process . Oil gas: Cracked petroleum for low molecular weight gases 6 Initial Coal Gas Period . 1812: First commercial plant chartered, London . First U.S. gas companies incorporated – 1817 Baltimore – 1823 New York – 1829 Boston 7 Advent of Water Gas . 1873: Lowe Carbureted Water Gas (CWG) Process patented; water gas provided superior illumination – 1884: Patents sold to United Gas Improvement Company – 1892: Lowe’s patents begin to expire . 1900: CWG accounts for 75% of U.S.
    [Show full text]
  • Coal-Modified Tar Binders for Bituminous Concrete Pavements
    Coal-Modified Tar Binders for Bituminous Concrete Pavements EDMUND O. RHODES, Curtiss-Wright Corporation, Pittsburgh, Pennsylvania In Fall 1958, investigations were started by the Re• search Division of Curtiss-Wright Corp. at Quehanna, Pa., with a view to developing improved methods for using bituminous coals and products derived there• from as highway construction materials. It was decided to explore the possibility of making an improved binder for bituminous pavements of the hot-mix hot-lay type by dispersing coal in distilled coal tars and coal tar oils. Previous investigations had indicated that they might also be used to advantage for the production of improved highway binders. During the first half of 1959 a task force at Que• hanna assembled and constructed suitable laboratory and pilot plant equipment; determined optimum condi• tions for the dispersion of coal m tars and oils; com• pared various coals, tars, and oils as to their suita• bility for the purpose; produced and analyzed experi• mental quantities of coal-modified tar binders; and combined them with various aggregates in hot mixes. The latter were then compared with hot mixes con• taining typical asphalt cements and coal-tar binders. The tests appeared to indicate that it would be possible to make hot mixes with coal-modified tar cements equal or superior to those made with usual asphalt or coal-tar binders. After the results of the Quehanna investigations were reported, a contract was made with the Com• monwealth of Kentucky to build a pilot plant at Frank• fort to produce 150,000 gal of coal-modified tar binder for comparison with asphalt cements normally used in Kentucky in Class I and Class I-modified bitumi• nous pavements.
    [Show full text]
  • Basic Skin Care and Topical Therapies for Atopic Dermatitis
    REVIEWS Basic Skin Care and Topical Therapies for Atopic Dermatitis: Essential Approaches and Beyond Sala-Cunill A1*, Lazaro M2*, Herráez L3, Quiñones MD4, Moro-Moro M5, Sanchez I6, On behalf of the Skin Allergy Committee of Spanish Society of Allergy and Clinical Immunology (SEAIC) 1Allergy Section, Internal Medicine Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain 2Allergy Department, Hospital Universitario de Salamanca, Alergoasma, Salamanca, Spain 3Allergy Department, Hospital Universitario 12 de Octubre, Madrid, Spain 4Allergy Section, Hospital Monte Naranco, Oviedo, Spain 5Allergy Department, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain 6Clínica Dermatología y Alergia, Badajoz, Spain *Both authors contributed equally to the manuscript J Investig Allergol Clin Immunol 2018; Vol. 28(6): 379-391 doi: 10.18176/jiaci.0293 Abstract Atopic dermatitis (AD) is a recurrent and chronic skin disease characterized by dysfunction of the epithelial barrier, skin inflammation, and immune dysregulation, with changes in the skin microbiota and colonization by Staphylococcus aureus being common. For this reason, the therapeutic approach to AD is complex and should be directed at restoring skin barrier function, reducing dehydration, maintaining acidic pH, and avoiding superinfection and exposure to possible allergens. There is no curative treatment for AD. However, a series of measures are recommended to alleviate the disease and enable patients to improve their quality of life. These include adequate skin hydration and restoration of the skin barrier with the use of emollients, antibacterial measures, specific approaches to reduce pruritus and scratching, wet wrap applications, avoidance of typical AD triggers, and topical anti-inflammatory drugs. Anti-inflammatory treatment is generally recommended during acute flares or, more recently, for preventive management.
    [Show full text]
  • Pharmacy Program and Drug Formulary
    Pharmacy Program and Drug Formulary Secure Horizons Group Retiree Medicare Advantage Plan n Pharmacy Program Description n Platinum Plus Enhanced Formulary California Benefits Effective January 1, 2006 Table of Contents Your Secure Horizons Group Retiree Medicare Advantage Plan Prescription Drug Benefit........................................................................................................ iii Secure Horizons Pharmacy Program Definitions .................................................................... iii What Is the Platinum Plus Enhanced Formulary? ....................................................................iv Where to Have Your Prescriptions Filled .................................................................................iv Preferred and Non-Preferred Network Pharmacies .................................................................iv Network Preferred Pharmacy Locations ..................................................................................iv How to Fill a Prescription at a Network Pharmacy ...................................................................v Mail Service Pharmacy ..............................................................................................................v Secure Horizons Group Retiree Medicare Advantage Plan Offers a Two-Part Prescription Drug Benefit ..........................................................................vii Part 1 – Medicare Part D Prescription Drug Coverage ...................................................vii How Your Medicare
    [Show full text]
  • Steroid Hormones Part Two
    Steroid Hormones Part Two Medicinal Chemistry III / 4th stage/ 1st Semester Lecture 9 Dr.Narmin Hama Amin Androgens Endogenous Androgens Testosterone and its more potent reduction product 5α-DHT are produced in significantly greater amounts in males than in females, but females also produce low amounts of these “male” sex hormones. Endogenous compounds have two important activities: ➢ Androgenic activity (promoting male sex characteristics) ➢ Anabolic activity (muscle building). ➢ Biosynthesis Testosterone can be synthesized through pregnenolone, DHEA(dehydroepiandrosterone) , and androstenedione Metabolism of Androgens ▪ Testosterone is rapidly converted to 5α-DHT in many tissues by the action of 5α-reductase. Depending on the tissue, this is either to activate testosterone to the more potent androgen, DHT (e.g., in the prostate), or a step in the metabolic inactivation of this androgen. The primary route for metabolic inactivation of testosterone and DHT is oxidation to the 17-one. The 3-one group is also reduced to the 3α- (major) and 3α- ols (minor). ▪ Androsterone is the major urinary metabolite and was the first “androgenic” steroid isolated. These metabolites are excreted mainly as the corresponding glucuronides Metabolism of Androgens SARs Of Androgens Testosterone exerts its physiological activity after its conversion to Dihydrotestosterone. A steroidal skeleton is minimum structural requirement to have androgenic activity. 17β hydroxyl function to be essential for androgenic and anabolic activity. Reduction of the A ring e.g., DHT may increase potency. Introduction of 17α methyl group confers oral activity on testosterone. Testosterone not effective orally, because metabolic changes at 17-β oxygen, which is used to attach the receptor site. 17-α alkyl groups prevent these metabolic changes so that compounds are orally active.
    [Show full text]